![]() | |
Names | |
---|---|
Preferred IUPAC name 1-(3-{4-[(piperidin-1-yl)methyl]phenoxy}propyl)piperidine | |
Identifiers | |
3D model (JSmol) | |
Abbreviations | JNJ-5207852 |
ChEMBL | |
ChemSpider |
|
MeSH | JNJ-5207852 |
UNII | |
| |
| |
Properties | |
C20H32N2O | |
Molar mass | 316.480 g/mol |
Except where otherwise noted, data are given for materials in theirstandard state (at 25 °C [77 °F], 100 kPa). |
JNJ-5207852 is ahistamine antagonist selective for theH3 subtype. It hasstimulant andnootropic effects in animal studies,[1] and has been suggested as a possible treatment for some memory defects associated withepilepsy.[2] JNJ-5207852 itself did not progress to clinical development due to poor pharmacokinetic characteristics, but the related compoundJNJ-17216498 was in a Phase II clinical trial for the treatment ofnarcolepsy in 2007.[3]
![]() | Thisdrug article relating to thenervous system is astub. You can help Wikipedia byexpanding it. |